RxDoctor Payments Data

Carol Denney

Family · Albany, KYNPI 1730245655

Payments from drug & device makers

$978in general payments, 2019–2025

Across 57 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$258
  • Pfizer$190
  • Vanda Pharmaceuticals Inc.$75
  • Amgen$58
  • GSK$57
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$50
  • plus $290 from 11 others

What the payments were for

  • Food & beverage$978100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$978 in reported general payments places this provider in the 65th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$607
Medicare patients
39
Services billed
57

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate89$62,811
XareltoRivaroxaban50$39,595
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$35,949
EliquisApixaban43$32,983
JardianceEmpagliflozin45$32,701
EntrestoSacubitril/Valsartan38$28,549
OzempicSemaglutide21$22,914
MounjaroTirzepatide18$21,878
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$18,527
TrulicityDulaglutide18$16,834
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$16,613
MyrbetriqMirabegron29$14,109
LinzessLinaclotide21$10,902
Combivent RespimatIpratropium/Albuterol Sulfate14$10,585
BrilintaTicagrelor22$9,246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$57$61,46092 claims
Boehringer IngelheimJardiance, Combivent Respimat$12$43,28659 claims
Lilly USA, LLCMounjaro, Trulicity$44$38,71236 claims
PfizerEliquis$190$32,98343 claims
NovartisEntresto$37$28,54938 claims
AstraZenecaBreztri Aerosphere, Brilinta$28$27,77450 claims
Novo NordiskOzempic$29$22,91421 claims
Astellas Pharma US IncMyrbetriq$46$14,10929 claims
AbbVieLinzess$258$10,90221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,374 family providers in Kentucky.

Other family in Albany

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →